Combination Therapy Shows 58% Risk Reduction in Metastatic dMMR Colorectal Cancer
Source Summary
A clinical trial published in the Journal of Clinical Oncology found that combining atezolizumab with modified FOLFOX6 chemotherapy and bevacizumab reduced the risk of disease progression or death by 58% in patients with metastatic dMMR or MSI-H colorectal cancer compared to atezolizumab alone. The combination therapy also achieved higher response rates and substantially reduced primary disease progression.
In depth
The NRG-GI004/SWOG S1610 COMMIT trial tested a multi-drug regimen in patients with metastatic colorectal cancer harboring deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). The trial compared atezolizumab, an immunotherapy checkpoint inhibitor, combined with modified FOLFOX6 chemotherapy and bevacizumab, an anti-angiogenic agent, versus atezolizumab monotherapy. Results demonstrated a 58% reduction in the composite risk of disease progression or death with the combination approach. The combination therapy also achieved higher overall response rates and meaningfully reduced the incidence of primary disease progression, establishing a new treatment benchmark for this patient population.
